CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 516 enrolled
Drug / intervention
Pegylated Interferon Alfa-2a +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01659567
NCT01659567N/ACompleted
CompareCT.gov

Prospective, Observational Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Patients With Hepatitis C in Georgia

Hoffmann-La Roche·observational·Posted Aug 8, 2012·Updated Oct 3, 2017

In Brief

An observational study evaluating Pegylated Interferon Alfa-2a and Ribavirin for Hepatitis C, Chronic. Completed, enrolled 516 participants across 3 sites.

Detailed Summary

This prospective observational study will investigate predictive values of virological response in pegylated interferon alfa-2a (Pegasys)/ribavirin (Copegus) treatment-naive participants with chronic hepatitis C. Participants will be treated with pegylated interferon alfa-2a and ribavirin as prescribed by the physician. Data will be collected for a maximum of 96 weeks.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Chronic
CountriesGeorgia
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 8, 2012
Enrollment StartApr 6, 2011
Primary CompletionOct 20, 2015
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 13.9 years ago

Interventions

Pegylated Interferon Alfa-2adrug

Pegylated interferon alfa-2a will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.

Ribavirindrug

Ribavirin will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.